RevBio: Funding, Investors & Team (Sep 2026)
RevBio is currently developing a bone adhesive biomaterial called Tetranite, which can be injected and sets on its own. This biomaterial has the ability to bond bone to bone and bone to metal even in a wet field setting. The company's flagship product, Tetranite, is currently being evaluated by the FDA for various applications in oral, craniofacial, orthopedic, and neurosurgical procedures. Unlike other products, this synthetic adhesive naturally degrades over time and is replaced by new bone. This innovative material has the potential to simplify and expedite medical procedures, enable less invasive surgeries, and enhance patient outcomes by reducing recovery time and overall medical expenses.
RevBio has raised $13.8M across 8 funding rounds on record, the most recent an undisclosed round of $2.2M announced in Oct 2025.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
RevBio Company Profile and Key Stats
Latest funding round on record: Oct 2025.
RevBio Funding Rounds
3 of 8 rounds were announced without a disclosed amount and are excluded from the total.
RevBio raised $5.2M in an undisclosed round announced in Jun 2021.
1 years later, a Non-equity Assistance was announced in Jun 2022 with no disclosed amount.
3 months later, a Grant was announced in Sep 2022 with no disclosed amount.
5 months later, an undisclosed round was announced in Feb 2023 with no disclosed amount.
4 months later, an undisclosed round of $2.0M was announced in Jun 2023.
4 months later, an undisclosed round of $2.0M was announced in Oct 2023.
11 months later, an undisclosed round of $2.4M was announced in Sep 2024.
1.1 years later, an undisclosed round of $2.2M was announced in Oct 2025.
RevBio Founders and Leadership Team
Contact details for the RevBio team: 3 of 4 have an email address on file.
Start 14-day free trial →RevBio Funding Compared to Other Biotechnology Startups
RevBio's latest round of $2.2M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like RevBio in Biotechnology and Lowell
Companies Similar to RevBio
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
RevBio Funding FAQs
What does RevBio do?
RevBio is currently developing a bone adhesive biomaterial called Tetranite, which can be injected and sets on its own. This biomaterial has the ability to bond bone to bone and bone to metal even in a wet field setting. The company's flagship product, Tetranite, is currently being evaluated by the FDA for various applications in oral, craniofacial, orthopedic, and neurosurgical procedures. Unlike other products, this synthetic adhesive naturally degrades over time and is replaced by new bone. This innovative material has the potential to simplify and expedite medical procedures, enable less invasive surgeries, and enhance patient outcomes by reducing recovery time and overall medical expenses.
How much funding has RevBio raised?
RevBio has raised $13.8M across 8 rounds on record. The most recent is an undisclosed round of $2.2M announced in Oct 2025.
When did RevBio last raise funding?
RevBio's most recent funding round on record is an undisclosed round of $2.2M, announced in Oct 2025.
Who founded RevBio?
FundedIQ lists Andrey Marchenko (Founder), Brian Hess (Founder), George Kay (Founder), Grayson Allen (Founder) at RevBio.
Where is RevBio headquartered?
RevBio is based in Lowell, Massachusetts, United States.
How many employees does RevBio have?
RevBio is in the 11-50 employee band.
How does RevBio's funding compare to other Biotechnology startups?
RevBio's latest round of $2.2M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's RevBio Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for RevBio is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.